Medicines By Design
Learn MoreViridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. In our lead programs, we are developing multiple product candidates that target the insulin-like growth factor-1 receptor (IGF-1R) to treat patients who suffer from thyroid eye disease (TED), a debilitating auto-immune disease.
Learn more about Viridian and our programs in our corporate presentation.
Recent Press Releases
- Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
- Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock and Preferred Stock
- Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock